JP2023164900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023164900A5 JP2023164900A5 JP2023139792A JP2023139792A JP2023164900A5 JP 2023164900 A5 JP2023164900 A5 JP 2023164900A5 JP 2023139792 A JP2023139792 A JP 2023139792A JP 2023139792 A JP2023139792 A JP 2023139792A JP 2023164900 A5 JP2023164900 A5 JP 2023164900A5
- Authority
- JP
- Japan
- Prior art keywords
- hdhfr
- wild type
- amino acids
- cells
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000908713 Homo sapiens Dihydrofolate reductase Proteins 0.000 claims 132
- 150000001413 amino acids Chemical class 0.000 claims 32
- 238000000034 method Methods 0.000 claims 26
- 210000001744 T-lymphocyte Anatomy 0.000 claims 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 102220242566 rs754509338 Human genes 0.000 claims 10
- 102220503901 Meiotic recombination protein REC8 homolog_D142G_mutation Human genes 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 102220227609 rs913563840 Human genes 0.000 claims 8
- 102220564041 Synphilin-1_K99R_mutation Human genes 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 102200080790 rs1057520333 Human genes 0.000 claims 6
- 102220159135 rs764865890 Human genes 0.000 claims 5
- 102220546996 Actin, gamma-enteric smooth muscle_I72K_mutation Human genes 0.000 claims 4
- 102220526135 Dihydrofolate reductase_N65F_mutation Human genes 0.000 claims 4
- 102000013462 Interleukin-12 Human genes 0.000 claims 4
- 108010065805 Interleukin-12 Proteins 0.000 claims 4
- 102000008300 Mutant Proteins Human genes 0.000 claims 4
- 108010021466 Mutant Proteins Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102220561604 SH2B adapter protein 2_W114R_mutation Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 102200013899 rs10258719 Human genes 0.000 claims 4
- 102200081454 rs1048108 Human genes 0.000 claims 4
- 102220078654 rs147697562 Human genes 0.000 claims 4
- 102200009188 rs148176750 Human genes 0.000 claims 4
- 102220257199 rs1553408408 Human genes 0.000 claims 4
- 102220283791 rs1555932650 Human genes 0.000 claims 4
- 102200065445 rs193929333 Human genes 0.000 claims 4
- 102220005448 rs28928876 Human genes 0.000 claims 4
- 102200127053 rs34177811 Human genes 0.000 claims 4
- 102220326936 rs45517095 Human genes 0.000 claims 4
- 102220232854 rs766277488 Human genes 0.000 claims 4
- 102220061202 rs786203440 Human genes 0.000 claims 4
- 102220072342 rs794728994 Human genes 0.000 claims 4
- 102220087418 rs864622444 Human genes 0.000 claims 4
- 102220087233 rs864622667 Human genes 0.000 claims 4
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims 3
- 102000003812 Interleukin-15 Human genes 0.000 claims 3
- 108090000172 Interleukin-15 Proteins 0.000 claims 3
- 108020001096 dihydrofolate reductase Proteins 0.000 claims 3
- 210000005259 peripheral blood Anatomy 0.000 claims 3
- 239000011886 peripheral blood Substances 0.000 claims 3
- 102220578645 Chorion-specific transcription factor GCMb_N65A_mutation Human genes 0.000 claims 2
- 102220578647 Chorion-specific transcription factor GCMb_N65D_mutation Human genes 0.000 claims 2
- 102220553748 Cyclic GMP-AMP synthase_K47R_mutation Human genes 0.000 claims 2
- 102220626226 DNA-directed primase/polymerase protein_M112T_mutation Human genes 0.000 claims 2
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 claims 2
- 102220526130 Dihydrofolate reductase_N65S_mutation Human genes 0.000 claims 2
- 102220526133 Dihydrofolate reductase_Q36K_mutation Human genes 0.000 claims 2
- 102220526132 Dihydrofolate reductase_Q36S_mutation Human genes 0.000 claims 2
- 102220545605 Endonuclease III-like protein 1_I176T_mutation Human genes 0.000 claims 2
- 102220467701 Ferrochelatase, mitochondrial_E172G_mutation Human genes 0.000 claims 2
- 102000003839 Human Proteins Human genes 0.000 claims 2
- 108090000144 Human Proteins Proteins 0.000 claims 2
- 102220511074 Hydroxycarboxylic acid receptor 3_E31D_mutation Human genes 0.000 claims 2
- 102220517095 Jerky protein homolog-like_I72V_mutation Human genes 0.000 claims 2
- 102220494567 Methionine synthase reductase_T40A_mutation Human genes 0.000 claims 2
- 102220525890 NADH-ubiquinone oxidoreductase chain 4L_I61T_mutation Human genes 0.000 claims 2
- 108010017405 NRH - quinone oxidoreductase2 Proteins 0.000 claims 2
- 101150098694 PDE5A gene Proteins 0.000 claims 2
- 102000000536 PPAR gamma Human genes 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 102220491272 Peripheral myelin protein 22_L80P_mutation Human genes 0.000 claims 2
- 102220516830 Peroxisomal membrane protein PEX14_K56E_mutation Human genes 0.000 claims 2
- 102220640878 Pregnancy-specific beta-1-glycoprotein 3_L23S_mutation Human genes 0.000 claims 2
- 102220533819 Protein BEX2_K19E_mutation Human genes 0.000 claims 2
- 102220467332 Protein BEX4_L94A_mutation Human genes 0.000 claims 2
- 102220621011 Protein SGT1 homolog_Y157R_mutation Human genes 0.000 claims 2
- 102100022353 Ribosyldihydronicotinamide dehydrogenase [quinone] Human genes 0.000 claims 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims 2
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims 2
- 102220419550 c.160G>A Human genes 0.000 claims 2
- 102220383755 c.422A>G Human genes 0.000 claims 2
- 102220363676 c.444T>G Human genes 0.000 claims 2
- 102220398030 c.50T>A Human genes 0.000 claims 2
- 102200061322 c.551A>G Human genes 0.000 claims 2
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 claims 2
- 230000001687 destabilization Effects 0.000 claims 2
- 238000003306 harvesting Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000005087 mononuclear cell Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102200147641 rs104894534 Human genes 0.000 claims 2
- 102220195383 rs1057517839 Human genes 0.000 claims 2
- 102200052983 rs1137100 Human genes 0.000 claims 2
- 102200111538 rs117209107 Human genes 0.000 claims 2
- 102200058933 rs121909535 Human genes 0.000 claims 2
- 102220280971 rs1253463092 Human genes 0.000 claims 2
- 102220289727 rs1253463092 Human genes 0.000 claims 2
- 102200090745 rs137852499 Human genes 0.000 claims 2
- 102200026990 rs137852764 Human genes 0.000 claims 2
- 102220131082 rs140691305 Human genes 0.000 claims 2
- 102220091389 rs145538358 Human genes 0.000 claims 2
- 102220288810 rs1554539977 Human genes 0.000 claims 2
- 102200004203 rs199472685 Human genes 0.000 claims 2
- 102220164875 rs199968672 Human genes 0.000 claims 2
- 102220150245 rs200516165 Human genes 0.000 claims 2
- 102220054003 rs201490017 Human genes 0.000 claims 2
- 102220294276 rs202032682 Human genes 0.000 claims 2
- 102200068687 rs281865206 Human genes 0.000 claims 2
- 102200068694 rs281865207 Human genes 0.000 claims 2
- 102200065572 rs28364364 Human genes 0.000 claims 2
- 102200082872 rs34866629 Human genes 0.000 claims 2
- 102200049497 rs386833427 Human genes 0.000 claims 2
- 102200037023 rs387907270 Human genes 0.000 claims 2
- 102220021057 rs397508897 Human genes 0.000 claims 2
- 102200164348 rs41295282 Human genes 0.000 claims 2
- 102220225986 rs537881554 Human genes 0.000 claims 2
- 102220044643 rs587781450 Human genes 0.000 claims 2
- 102200001847 rs587782995 Human genes 0.000 claims 2
- 102200027869 rs62517167 Human genes 0.000 claims 2
- 102200119608 rs62641235 Human genes 0.000 claims 2
- 102200103842 rs6436669 Human genes 0.000 claims 2
- 102220032039 rs67418243 Human genes 0.000 claims 2
- 102200101879 rs72556290 Human genes 0.000 claims 2
- 102200101881 rs72556293 Human genes 0.000 claims 2
- 102220057450 rs730881811 Human genes 0.000 claims 2
- 102220286181 rs730881811 Human genes 0.000 claims 2
- 102200094314 rs74315399 Human genes 0.000 claims 2
- 102220277052 rs757815307 Human genes 0.000 claims 2
- 102220082831 rs780379280 Human genes 0.000 claims 2
- 102220063397 rs786204865 Human genes 0.000 claims 2
- 102220323326 rs796360127 Human genes 0.000 claims 2
- 102220022272 rs80357266 Human genes 0.000 claims 2
- 102200067619 rs80357382 Human genes 0.000 claims 2
- 102220096012 rs876658305 Human genes 0.000 claims 2
- 102200004551 rs886038212 Human genes 0.000 claims 2
- 102220118255 rs886041732 Human genes 0.000 claims 2
- 102220119381 rs886042300 Human genes 0.000 claims 2
- 102220235606 rs925977838 Human genes 0.000 claims 2
- 102220279469 rs992385562 Human genes 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 102220010999 rs104894360 Human genes 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762466601P | 2017-03-03 | 2017-03-03 | |
| US62/466,601 | 2017-03-03 | ||
| US201762484052P | 2017-04-11 | 2017-04-11 | |
| US62/484,052 | 2017-04-11 | ||
| PCT/US2018/020741 WO2018161017A1 (en) | 2017-03-03 | 2018-03-02 | Cd19 compositions and methods for immunotherapy |
| JP2019568594A JP7341900B2 (ja) | 2017-03-03 | 2018-03-02 | 免疫療法のためのｃｄ１９組成物及び方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568594A Division JP7341900B2 (ja) | 2017-03-03 | 2018-03-02 | 免疫療法のためのｃｄ１９組成物及び方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025165390A Division JP2025185029A (ja) | 2017-03-03 | 2025-10-01 | 免疫療法のためのｃｄ１９組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023164900A JP2023164900A (ja) | 2023-11-14 |
| JP2023164900A5 true JP2023164900A5 (enExample) | 2024-04-12 |
Family
ID=63371272
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568594A Active JP7341900B2 (ja) | 2017-03-03 | 2018-03-02 | 免疫療法のためのｃｄ１９組成物及び方法 |
| JP2023139792A Pending JP2023164900A (ja) | 2017-03-03 | 2023-08-30 | 免疫療法のためのｃｄ１９組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568594A Active JP7341900B2 (ja) | 2017-03-03 | 2018-03-02 | 免疫療法のためのｃｄ１９組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3589646A4 (enExample) |
| JP (2) | JP7341900B2 (enExample) |
| KR (1) | KR102746901B1 (enExample) |
| CN (1) | CN110831961B (enExample) |
| AU (2) | AU2018227583B2 (enExample) |
| CA (1) | CA3055202A1 (enExample) |
| SG (2) | SG11201907922PA (enExample) |
| WO (1) | WO2018161017A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| SG11201912010XA (en) | 2017-06-12 | 2020-01-30 | Obsidian Therapeutics Inc | Pde5 compositions and methods for immunotherapy |
| US10785574B2 (en) | 2017-12-14 | 2020-09-22 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
| WO2019118918A1 (en) | 2017-12-15 | 2019-06-20 | Aleta Biotherapeutics Inc. | Cd19 variants |
| CN119752801A (zh) * | 2018-08-01 | 2025-04-04 | 南克维斯特公司 | 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统 |
| WO2020068631A1 (en) * | 2018-09-24 | 2020-04-02 | Merck Sharp & Dohme Corp. | Expression vectors for eukaryotic expression systems |
| US11547727B2 (en) * | 2018-11-06 | 2023-01-10 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells |
| US12109238B2 (en) | 2018-11-06 | 2024-10-08 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells |
| CN118497276A (zh) * | 2018-11-07 | 2024-08-16 | 阿库斯股份有限公司 | 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途 |
| US12227551B2 (en) | 2018-12-11 | 2025-02-18 | Obsidian Therapeutics, Inc. | Membrane bound IL12 compositions and methods for tunable regulation |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| CN113412117B (zh) | 2018-12-12 | 2025-03-04 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
| JP2022523502A (ja) * | 2019-01-29 | 2022-04-25 | シャンハイ ジャオ トン ユニバーシティ | キメラ抗原受容体およびその使用 |
| JP6821230B2 (ja) | 2019-02-04 | 2021-01-27 | 国立大学法人愛媛大学 | ＣＡＲライブラリおよびｓｃＦｖの製造方法 |
| AU2020224160A1 (en) * | 2019-02-21 | 2021-08-26 | John M. LUK | Artificial immunosurveillance chimeric antigen receptor (AI-CAR) and cells expressing the same |
| US12006345B2 (en) | 2019-02-21 | 2024-06-11 | Xencor, Inc. | Untargeted and targeted IL-10 Fc-fusion proteins |
| US20220144917A1 (en) | 2019-03-01 | 2022-05-12 | Universität Für Bodenkultur Wien | Stabilized extracellular domain of cd19 |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| US20220175781A1 (en) * | 2019-03-08 | 2022-06-09 | Obsidian Therapeutics, Inc. | Cd40l compositions and methods for tunable regulation |
| SG11202109172TA (en) * | 2019-03-08 | 2021-09-29 | Obsidian Therapeutics Inc | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
| CN113710697A (zh) * | 2019-03-15 | 2021-11-26 | 美国政府(由卫生和人类服务部的部长所代表) | 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途 |
| BR112021021178A2 (pt) | 2019-04-26 | 2022-03-15 | Allogene Therapeutics Inc | Receptores de antígeno quimérico resistentes ao rituximabe e usos destes |
| CN110079504A (zh) * | 2019-05-06 | 2019-08-02 | 山东大学第二医院 | 一种含有不稳定结构域的car-t细胞及其制备方法和调节car-t细胞功能方法 |
| CN110075275B (zh) * | 2019-05-15 | 2023-03-24 | 苏州大学 | IL-36β的应用 |
| US20220162644A1 (en) * | 2019-05-29 | 2022-05-26 | Orbis Health Solutions, Llc | Delivery vectors and particles for expressing chimeric receptors and methods of using the same |
| BR112021025022A2 (pt) * | 2019-06-12 | 2022-02-22 | Obsidian Therapeutics Inc | Composições de ca2 e métodos para regulação ajustáveis |
| US20220249640A1 (en) * | 2019-06-14 | 2022-08-11 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-1 and methods of use thereof |
| CN110818803B (zh) * | 2019-07-24 | 2023-01-03 | 浙江启新生物技术有限公司 | 分泌表达il15ra-il15融合蛋白、ccl21趋化因子的嵌合抗原受体-t细胞及应用 |
| WO2021034952A1 (en) * | 2019-08-19 | 2021-02-25 | Elpis Biopharmaceuticals | Anti-cd19 antibodies and uses thereof |
| WO2021041725A1 (en) * | 2019-08-27 | 2021-03-04 | The Trustees Of The Univeristy Of Pennsylvania | SYNTHETIC CARS TO TREAT IL13Rα2 POSITIVE HUMAN AND CANINE TUMORS |
| US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
| WO2021046451A1 (en) * | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| EP4028413A1 (en) | 2019-09-10 | 2022-07-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| EP4041297A4 (en) * | 2019-10-11 | 2024-02-28 | The Trustees of The University of Pennsylvania | COMPOSITIONS AND METHODS FOR TARGETING CD13 AND TIM-3 WITH CAR-T CELLS FOR TREATING ACUTE MYELOID LEUKEMIA |
| KR20220128988A (ko) * | 2019-11-27 | 2022-09-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 항-cd3 scfv 및 사이토카인 생산용 인공 항원 제시 세포 |
| AU2020393906A1 (en) * | 2019-11-27 | 2022-06-23 | Board Of Regents, The University Of Texas System | Large-scale combined car transduction and CRISPR gene editing of T cells |
| AU2021205416A1 (en) * | 2020-01-08 | 2022-08-25 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| AU2021219886B2 (en) * | 2020-02-13 | 2025-01-23 | Beijing Immunochina Pharmaceuticals Co., Ltd. | Optimization of chimeric antigen receptor |
| KR20210103975A (ko) * | 2020-02-14 | 2021-08-24 | (주)이뮤노텍바이오팜코리아 | 외부에서 도입된 세포 신호 조절 인자를 과발현하는 면역 세포 및 이들의 용도 |
| CA3173981A1 (en) * | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of npm1c-positive cancer |
| CN113214396B (zh) * | 2020-07-31 | 2022-04-19 | 北京市神经外科研究所 | 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途 |
| CA3191047A1 (en) * | 2020-09-02 | 2022-03-10 | James Barnaby Trager | Enhanced expansion and cytotoxicity of engineered natural killer cells and uses thereof |
| US20230220025A1 (en) * | 2020-09-04 | 2023-07-13 | Heartseed Inc. | Quality Improving Agent for IPS Cells, Method of Producing IPS Cells, IPS Cells, and Composition for Producing IPS Cells |
| US20240002479A1 (en) * | 2020-11-23 | 2024-01-04 | The Regents Of The University Of Michigan | Single-chain antibody against flavivirus ns1 protein |
| CN112795543B (zh) * | 2021-02-04 | 2022-09-27 | 华中农业大学 | 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用 |
| CN113403274B (zh) * | 2021-06-28 | 2023-11-10 | 上海睿臻迈生物医疗科技有限公司 | 细胞治疗组合物及其制备方法和作为过敏性反应及自身免疫疾病治疗药物的应用 |
| CN113736810B (zh) * | 2021-09-08 | 2024-05-24 | 苏州因特药物研发有限公司 | 构建体、载体、蛋白、细胞、制备方法、产品及应用 |
| CN114129718B (zh) * | 2021-10-19 | 2024-05-03 | 华东师范大学 | 一种用于体内自组装car-t的纳米递送系统及其制备方法和应用 |
| CN114558126B (zh) * | 2021-11-04 | 2024-11-08 | 苏州大学附属第一医院 | 序贯输注cd19 car-t和bcma car-t细胞在急性白血病患者免疫介导血小板输注无效中的联合应用 |
| US20250332197A1 (en) * | 2022-03-18 | 2025-10-30 | Sunshine Lake Pharma Co., Ltd. | Claudin18.2 humanized antibody and application thereof |
| KR20250034432A (ko) | 2022-07-05 | 2025-03-11 | 네오믹스 파마슈티컬즈 엘엘씨 | 키메라 세포내 신호전달 도메인에 연결된 bcma 나노바디를 포함하는 키메라 항원 수용체 |
| KR20250164239A (ko) * | 2023-03-15 | 2025-11-24 | 교토후고리츠다이가쿠호진 | 펩티드 발현 구축물 및 그의 용도 |
| CN116516007B (zh) * | 2023-04-18 | 2024-01-19 | 华中科技大学同济医学院附属协和医院 | Cd19表达的检测方法 |
| CN116536375B (zh) * | 2023-06-28 | 2023-11-10 | 北京大学深圳研究生院 | merocyclophanes类化合物的化学-酶法合成方法及其应用 |
| WO2025160432A1 (en) * | 2024-01-26 | 2025-07-31 | Poseida Therapeutics, Inc. | Methods and compositions for enhancing in vivo persistence and potency of cell therapy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4733635B2 (ja) * | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ１９抗体 |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| KR100787393B1 (ko) * | 2006-03-23 | 2007-12-21 | 학교법인 한림대학교 | 세포 도입성 ｆｋ506 결합 단백질의 융합 단백질 |
| US8173792B2 (en) | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
| US8530636B2 (en) * | 2008-05-07 | 2013-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells in vivo using synthetic small molecules |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9868774B2 (en) * | 2011-10-20 | 2018-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD22 chimeric antigen receptors |
| WO2013172926A1 (en) * | 2012-05-14 | 2013-11-21 | Yale University | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer |
| DK2956175T3 (da) * | 2013-02-15 | 2017-11-27 | Univ California | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf |
| WO2014152932A1 (en) * | 2013-03-14 | 2014-09-25 | Board Of Regents, The University Of Texas System | Mirna for treating cancer and for use with adoptive immunotherapies |
| ES2828982T3 (es) * | 2013-05-14 | 2021-05-28 | Univ Texas | Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas |
| EP3038619B1 (en) * | 2013-08-28 | 2023-10-04 | PCI Biotech AS | Compound and method for vaccination and immunisation |
| AU2014337367B2 (en) * | 2013-10-15 | 2020-04-30 | The Scripps Research Institute | Peptidic chimeric antigen receptor T cell switches and uses thereof |
| US11382963B2 (en) * | 2015-01-12 | 2022-07-12 | Pieris Pharmaceuticals Gmbh | Engineered T cells and uses therefor |
| US11248058B2 (en) * | 2015-02-19 | 2022-02-15 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
| WO2017180587A2 (en) * | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| SG11201900677SA (en) * | 2016-07-28 | 2019-02-27 | Novartis Ag | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors |
| SG11201912010XA (en) * | 2017-06-12 | 2020-01-30 | Obsidian Therapeutics Inc | Pde5 compositions and methods for immunotherapy |
-
2018
- 2018-03-02 JP JP2019568594A patent/JP7341900B2/ja active Active
- 2018-03-02 KR KR1020197029002A patent/KR102746901B1/ko active Active
- 2018-03-02 CN CN201880025103.XA patent/CN110831961B/zh active Active
- 2018-03-02 EP EP18760420.2A patent/EP3589646A4/en active Pending
- 2018-03-02 AU AU2018227583A patent/AU2018227583B2/en active Active
- 2018-03-02 SG SG11201907922PA patent/SG11201907922PA/en unknown
- 2018-03-02 CA CA3055202A patent/CA3055202A1/en active Pending
- 2018-03-02 SG SG10202001869VA patent/SG10202001869VA/en unknown
- 2018-03-02 WO PCT/US2018/020741 patent/WO2018161017A1/en not_active Ceased
-
2023
- 2023-08-11 AU AU2023214349A patent/AU2023214349A1/en active Pending
- 2023-08-30 JP JP2023139792A patent/JP2023164900A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023164900A5 (enExample) | ||
| US20250288655A1 (en) | Inducible regulatory t-cell generation for hematopoietic transplants | |
| Oeser et al. | Conditional IL-4/IL-13-deficient mice reveal a critical role of innate immune cells for protective immunity against gastrointestinal helminths | |
| KR102389096B1 (ko) | Flt3에 대한 키메라 수용체 및 이의 사용 방법 | |
| JP6793902B2 (ja) | 調節可能キメラ抗原受容体 | |
| JP2022033832A (ja) | 消化管炎症低下および／または消化管粘膜バリア強化の利益を享受する疾患処置のために操作された細菌 | |
| Kawabe et al. | Homeostatic proliferation of naive CD4+ T cells in mesenteric lymph nodes generates gut-tropic Th17 cells | |
| BR112020005361A2 (pt) | anticorpos anti-hla-a2 e métodos de uso dos mesmos | |
| TW202041529A (zh) | 嵌合受體和使用彼之方法 | |
| JP2017528433A (ja) | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ | |
| TW202019954A (zh) | 用於治療傳染病之共受體系統 | |
| CN113795263A (zh) | 包含可负载抗原呈递多肽的工程化红系细胞及使用方法 | |
| RU2012127380A (ru) | Гуманизированные антитела против il-10 для лечения системной красной волчанки (slt) | |
| JP2018506995A5 (enExample) | ||
| Latham et al. | Ex vivo characterization of the autoimmune T cell response in the HLA-DR1 mouse model of collagen-induced arthritis reveals long-term activation of type II collagen-specific cells and their presence in arthritic joints | |
| JP2020528455A (ja) | ドナー改変細胞の選択のための調節可能スイッチ | |
| US10758568B2 (en) | Regulatory T-cells for use in the treatment of inflammatory disorders of the human gastrointestinal tract | |
| Wu et al. | A method for expansion and retroviral transduction of mouse regulatory T cells | |
| Taylor et al. | Cloning and characterization of antiviral cytotoxic T lymphocytes in channel catfish, Ictalurus punctatus | |
| Oldstone | The role of cytotoxic T lymphocytes in infectious disease: history, criteria, and state of the art | |
| CN109803681A (zh) | 用于治疗免疫病症的免疫抑制组合物 | |
| Liu et al. | SH2D1A expression reflects activation of T and NK cells in cord blood lymphocytes infected with EBV and treated with the immunomodulator PSK | |
| TWI904120B (zh) | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 | |
| US20230287080A1 (en) | T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells | |
| US20230287346A1 (en) | T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells |